H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on C4 Therapeutics to $17 from $25 and keeps a Buy rating on the shares. The analyst expects the stock to be rangebound toward its 52-week low until CFT7455 safety profile is deemed a “non-liability to the program.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics expects cash to fund operations into 2H25
- C4 Therapeutics announces upcoming milestones
- C4 Therapeutics reports Q2 EPS (73c), consensus (69c)
- C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics price target lowered to $20 from $22 at UBS